LCI-HEM-SPEC-001: Tissue Collection for Genetic Analysis of Acute Myelogenous Leukemia
Conditions
Leukemia, Myelogenous, Acute
Conditions: official terms
Leukemia - Leukemia, Myeloid - Leukemia, Myeloid, Acute
Study Type
Observational
Study Phase
N/A
Study Design
Time Perspective: Prospective
Overall Status
Recruiting
Summary
The purpose of this study is to obtain high quality specimens for molecular studies for the identification and characterization of genetic mutations involved in the pathogenesis of familial myeloid malignancies. Specimens obtained will be de-identified, linked to basic clinical data, and sent to Washington University (Division of Oncology, St. Louis, MO) for molecular analyses. Some specimens sent to Washington University may also be used for quality control analyses.
Detailed Description
This is a specimen collection study for patients receiving standard of care treatment for AML. Specimens collected will be 1) bone marrow biopsy and aspiration, 2) peripheral blood, 3) skin punch biopsy, and 4) oral rinse. Collection of these specimens will be at timepoints determined by the patient's standard of care and their physician Investigator.
Criteria for eligibility
Healthy Volunteers: Accepts Healthy Volunteers
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria

- Patients must have a diagnosis of acute myelogenous leukemia.

- Family members of patients with acute myelogenous leukemia may be enrolled.

- Informed consent must be provided by the patient or his/her legal guardian in accord with the practices of Levine Cancer Institute and Carolinas Healthcare System.

Exclusion Criteria

- Known infection with Hepatitis B or C, HTLV, or HIV.
Location
Levine Cancer Institute
Charlotte, North Carolina, United States
Status: Recruiting
Start Date
November 2013
Completion Date
September 2018
Sponsors
Belinda Avalos
Source
Carolinas Healthcare System
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page